Revvity, 63ADK113PEH, HTRF SARS-CoV2 Nucleocapsid Detection Kit, 10,000 Assay Points

The SARS-CoV-2 N protein is the basal monomeric constituent of the coronavirus oligomeric nucleocapsid. This protein is major immunogen predominantly expressed at early stages of viral infection and present from day one in infected patients' serum. As such, SARS-CoV-2 N protein is a reliable marker for viral infection and a possible immunogen candidate for the development of a vaccine. HTRF assays offer many advantages over other technologies: Homogeneous add-and-read format No wash steps Low background Straightforward miniaturization from 96- or 384-well microplates to high density assay formats such as 384-well low volume and 1536-well plates Stable signal, providing flexibility in time of readout or size of assays
SARS-CoV-2 particles are detected in cell lysates using a sandwich immunoassay involving an anti-nucleocapsid monoclonal antibody, labelled with terbium-Cryptate or d2, ensuring assay quality, reproducibility, and signal quality. The specific HTRF signal generated is proportional to the amount of nucleocapsid proteins. The assay protocol, using a 384-well small volume plate or a low volume 96 well plate (20 µL final), is described on the right. 16 µL of cell lysates or control are dispensed directly into the detection plate for detection by HTRF reagents. The antibodies labelled with HTRF donor and acceptor can be pre-mixed and added in a single dispensing step to further streamline the assay procedure (4 µL), or separately (2 µL).